Drugs / OPT-822/OPT-821
OPT-822/OPT-821
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02132988 | Nov 2013 → Nov 2017 | ovarian cancer | Mackay Memorial Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2016-07-27 | OBI Pharma, Inc | Results Quick Takes on Promising New Approaches to Treating Breast Cancer obipharma.com ↗
The primary synthroidnews.net was not met, but we saw a very provocative result in IgG/IgM responders…. Further development is clearly warranted. |
| 2016-06-05 | OBI Pharma, Inc | Results OBI Pharma Presents Data for Novel Investigational OBI-822/OBI-821 in Patients with Metastatic Breast Cancer at the 2016 American Society of Clinical Oncology Annual Meeting obipharma.com ↗
The study did not meet the primary efficacy end point of progression-free survival (PFS) in patients with late stage metastatic breast cancer. |
| 2016-05-19 | OBI Pharma, Inc | Results OBI’s Abstract at ASCO 2016: Randomized Phase 2/3 Trial of Active Immunotherapy With OPT-822/OPT-821 in Patients With Metastatic Breast Cancer obipharma.com ↗
No difference was observed in PFS (HR=0.96 [95%CI 0.74-1.25] p=0.77); or in interim OS (HR=0.79 [95%CI 0.51-1.22] p=0.29). |
| 2016-02-21 | OBI Pharma, Inc | Results OBI Pharma Reports Topline Results from OBI-822/821 Randomized Controlled Phase 2/3 Clinical Trial in Patients with Metastatic Breast Cancer obipharma.com ↗
OBI Pharma, Inc., a Taiwan biotech company (TPex: 4174), today announced the topline results of the Phase 2/3 study of OBI-822/821 (formerly OPT‐822/OPT‐821), which evaluated the clinical benefit and immunogenicity of the investigational immunotherapy in patients with metastatic breast cancer. |
All press releases naming this drug 4 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPT-822/OPT-821 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02132988 ↗ |
| Known as | Globo H-KLH | “Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer” NCT02132988 ↗ |
| Known as | OPT-822/821 | “Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer” NCT02132988 ↗ |